SMS PharmaceuticalsBOM:532815 +8.58%71 EBITDA Margin % is 17.85% as of Mar. 2026, which is 12% below its 10-year median of 20.20. GuruFocus rates BOM:532815 with a GF Score™ of 71/100 and a GF Value™ of ₹262.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 953 Drug Manufacturers companies, SMS Pharmaceuticals ranks better than 68.52% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SMS Pharmaceuticals EBITDA Margin % Related Terms
SMS Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SMS Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532815 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, SMS Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMS Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SMS Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SMS Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMS Pharmaceuticals (BOM:532815) has a EBITDA Margin % of 17.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SMS Pharmaceuticals and its competitors. This is 12% below median its historical median of 20.20. Over the past decade, SMS Pharmaceuticals' EBITDA Margin % has ranged from 11.25 to 23.07. According to the industry distribution chart, SMS Pharmaceuticals ranks #300 out of 953 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is SMS Pharmaceuticals' EBITDA Margin % too high?
SMS Pharmaceuticals' current EBITDA Margin % of 17.85% is 12% below median its 10-year median of 20.20. Over the past 10 years, this metric has ranged from a low of 11.25 to a high of 23.07. The Drug Manufacturers industry median EBITDA Margin % is 12.54. SMS Pharmaceuticals' value of 17.85% is 42.3% above this industry median. Based on the distribution chart, SMS Pharmaceuticals ranks #300 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SMS Pharmaceuticals has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SMS Pharmaceuticals' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SMS Pharmaceuticals ranks #300 out of 953 companies for EBITDA Margin %. This puts SMS Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.54. SMS Pharmaceuticals' value of 17.85% is 42.3% above this benchmark. Historically, SMS Pharmaceuticals' own EBITDA Margin % has ranged from 11.25 to 23.07 over the past decade. While the company's 10-year median is 20.20 vs. the industry median of 12.54, SMS Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SMS Pharmaceuticals's current EBITDA Margin % of 17.85% is 42.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SMS Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMS Pharmaceuticals's current EBITDA Margin % is 17.85%, which is 12% below median its own 10-year median of 20.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SMS Pharmaceuticals (BOM:532815) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹262.38, compared to a current price of ₹413.10 — trading 57.4% above its estimated fair value. The current EBITDA Margin % is 17.85%, which is 12% below median its 10-year median of 20.20 and 42.3% above the Drug Manufacturers industry median of 12.54. SMS Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SMS Pharmaceuticals (BOM:532815), the current EBITDA Margin % is 17.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMS Pharmaceuticals (BOM:532815) Overvalued in 2026?
Based on GuruFocus' analysis, SMS Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹413.10 is trading 57.4% above its estimated GF Value™ of ₹262.38.
GuruFocus considers SMS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:532815:
EBITDA Margin %: 17.85% (12% below median its 10-year median of 20.20)
GF Value™: ₹262.38 vs. price of ₹413.10 (57.4% above fair value)
Industry Position: 42.3% above the Drug Manufacturers median (#300 of 953)
No single metric tells the full story. See the BOM:532815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the business of manufacturing Active Pharma Ingredients and their intermediates. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, and other conditions.
71GF Score
Get the complete analysis for BOM:532815
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532815 has been successfully added to your 
